<DOC>
	<DOCNO>NCT01443364</DOCNO>
	<brief_summary>The study aim evaluate predictability early response Certolizumab pegol combination Methotrexate one year patient moderate severe rheumatoid arthritis .</brief_summary>
	<brief_title>Open Label Study Assess Predictability Early Response Certolizumab Pegol Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>diagnosis adultonset Rheumatoid Arthritis ( RA ) duration least 6 month longer 5 year positive Rheumatoid Factor ( RF ) and/or positive anti Cyclic Citrullinated Peptide ( antiCCP ) active RA disease subject must fail least one traditional Disease Modifying AntiRheumatic Drug ( DMARD ) . subject na√Øve RA relate biologics diagnosis inflammatory arthritis history infect joint prosthesis , significant infection know Tuberculosis ( TB ) disease high risk acquire TB infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Certolizumab pegol - Cimzia</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Power Doppler Ultrasonography</keyword>
	<keyword>Italy</keyword>
	<keyword>Moderate-severe Rheumatoid Arthritis</keyword>
</DOC>